Results up to week 52 in the phase 3 study show that primary end points were met for best corrected visual acuity and central subfield thickness.
One-year results of a phase 3 study of a proposed ranibizumab biosimilar (SB11) in patients with neovascular age-related macular degeneration have shown equivalence in efficacy and pharmacokinetics (PK), as well as comparable safety and immunogenicity to the reference product, according to Samsung Bioepis.
Results of the study will be presented at the American Academy of Ophthalmology 2020 Virtual meeting from November 13 to 15, 2020.
Investigators enrolled 705 patients and said that 634 patients completed the study up to week 52. They said that clinical end points, defined as changes from baseline in best corrected visual acuity (BCVA) at week 8 and central subfield thickness (CST) at week 4, were met.
Long-term efficacy, safety, PK, and immunogenicity were secondary end points, and findings were comparable between SB11 and the reference product (Lucentis).
In the randomized, double-blind, multicenter study, the 8-week mean change in eye chart letters read correctly from baseline in BCVA at week 8 was –0.8 letters (90% CI, –1.8 to 0.2) between SB11 and reference ranibizumab. The mean change from CST baseline at week 4 was an adjusted treatment difference of −8 mcm (95% CI, −19 to 3 mcm) between SB11 and the reference agent.
The mean change from baseline in BCVA by week 52 was 9.79 letters for SB11 vs 10.41 letters for reference ranibizumab (difference: –0.62 [90% CI, −2.092 to 0.857]).
The mean change in CST was −139.55 mcm for SB11 compared with −124.46 mcm for reference ranibizumab (difference: −15.09 [95% CI, −25.617 to −4.563 mcm]).
Investigators said that PK, safety, and immunogenicity between the biosimilar candidate and reference product were comparable at all time points up to week 52.
In May 2020, Samsung Bioepis reported 24-week interim results from the same study.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.